Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints

Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.